Recommendations to overcome barriers to the use of artificial intelligence-driven evidence in health technology assessment

Recommendations to overcome barriers to the use of artificial intelligence-driven evidence in health technology assessment

BackgroundArtificial intelligence (AI) has attracted much attention because of its enormous potential in healthcare, but uptake has been slow. There are substantial barriers that challenge health technology assessment (HTA) professionals to use AI-generated evidence for decision-making from large re...

Full description

Bibliographic Details
Main Authors:	Antal Zemplényi, Konstantin Tachkov, Laszlo Balkanyi, Bertalan Németh, Zsuzsanna Ida Petykó, Guenka Petrova, Marcin Czech, Dalia Dawoud, Wim Goettsch, Inaki Gutierrez Ibarluzea, Rok Hren, Saskia Knies, László Lorenzovici, Zorana Maravic, Oresta Piniazhko, Alexandra Savova, Manoela Manova, Tomas Tesar, Spela Zerovnik, Zoltán Kaló
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-04-01
Series:	Frontiers in Public Health
Subjects:	artificial intelligence—AI machine learning health technology assessment evidence generation Central and Eastern Europe
Online Access:	https://www.frontiersin.org/articles/10.3389/fpubh.2023.1088121/full

Similar Items

Guidance on using real-world evidence from Western Europe in Central and Eastern European health policy decision making
by: Bertalan Nemeth, et al.
Published: (2023-03-01)

Recommendations for patient involvement in health technology assessment in Central and Eastern European countries
by: Ivett Jakab, et al.
Published: (2023-07-01)

Potential Barriers of Patient Involvement in Health Technology Assessment in Central and Eastern European Countries
by: Maria Dimitrova, et al.
Published: (2022-07-01)

Barriers to Use Artificial Intelligence Methodologies in Health Technology Assessment in Central and East European Countries
by: Konstantin Tachkov, et al.
Published: (2022-07-01)

An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries
by: Maria Kamusheva, et al.
Published: (2018-03-01)

Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges
by: Rita Daubner-Bendes, et al.
Published: (2021-01-01)

Comparison of Cardiovascular Medicines Prices in Four European Countries
by: Zornitsa Mitkova, et al.
Published: (2020-08-01)

Delayed payment schemes in Central-Eastern Europe and Middle-East
by: Ildikó Ádám, et al.
Published: (2022-08-01)

Generic policy in Bulgaria: a policy of failure or success?
by: Assena Stoimenova, et al.
Published: (2016-09-01)

Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries
by: Maria Kamusheva, et al.
Published: (2018-07-01)

Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis
by: Manoela Manova, et al.
Published: (2018-09-01)

Аn affordability of statins therapy - comparative analysis between Ukraine and Bulgaria
by: Oksana Tkachova, et al.
Published: (2019-11-01)

Identifying Patient Access Barriers for Tumor Necrosis Factor Alpha Inhibitor Treatments in Rheumatoid Arthritis in Five Central Eastern European Countries
by: András Inotai, et al.
Published: (2020-06-01)

Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria
by: Monika Russel-Szymczyk, et al.
Published: (2019-12-01)

Cost Assessment of Inpatient Care Episodes of Stroke in Romania
by: László Lorenzovici, et al.
Published: (2020-12-01)

Micro and macro analysis on the burden of COPD hospitalizations on the Bulgarian healthcare system
by: Konstantin Tachkov, et al.
Published: (2019-01-01)

Burden of Chronic Heart Failure in Romania
by: László Lorenzovici, et al.
Published: (2022-01-01)

Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary
by: Vokó Zoltán, et al.
Published: (2012-10-01)

Outcome-based reimbursement in Central-Eastern Europe and Middle-East
by: Ildikó Ádám, et al.
Published: (2022-09-01)

Incretins and SGLT-2i Therapy of Type 2 Diabetes – Real Life Study of Their Therapeutic and Economic Effects
by: Zornitsa Mitkova, et al.
Published: (2019-04-01)

Improved quality of diabetes control reduces complication costs in Bulgaria
by: Konstantin Tachkov, et al.
Published: (2019-01-01)

Life expectancy and survival analysis of patients with diabetes compared to the non diabetic population in Bulgaria.
by: Konstantin Tachkov, et al.
Published: (2020-01-01)

Implementation of palliative care consult Service in Hungary – integration barriers and facilitators
by: Antal T. Zemplényi, et al.
Published: (2020-03-01)

Cost-Utility Analysis of Heberprot-P as an Add-on Therapy to Good Wound Care for Patients in Slovakia with Advanced Diabetic Foot Ulcer
by: Tomas Tesar, et al.
Published: (2017-12-01)

Cost-effectiveness of different types of COH protocols for in vitro fertilization at national level
by: Boriana Benbassat, et al.
Published: (2017-01-01)

A Systematic Review of Collective Evidences Investigating the Effect of Diabetes Monitoring Systems and Their Application in Health Care
by: Maria Kamusheva, et al.
Published: (2021-03-01)

Predicting the outcomes and costs for a cohort of 426 patients with Chronic Obstructive Pulmonary Disease (COPD) in Bulgaria through a Markov model
by: Konstantin Tachkov, et al.
Published: (2019-07-01)

Mapping Hungarian procedure codes to SNOMED CT
by: Ágota Mészáros, et al.
Published: (2023-10-01)

Nyugdíjreform-dilemmák – jövedelemelosztási arányok és makropénzügyi egyensúly
by: László Antal
Published: (2008-06-01)

Budget Impact of Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Chronic Heart Failure and Iron Deficiency in Romania
by: Lorenzovici László, et al.
Published: (2019-12-01)

Planning, implementation and operation of a personalized patient management system for subjects with first suspect of cancer (OnkoNetwork): system description based on a qualitative study
by: János G. Pitter, et al.
Published: (2019-02-01)

Synergy between health technology assessments and clinical guidelines for multiple sclerosis
by: Milou A. Hogervorst, et al.
Published: (2023-05-01)

Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
by: Krzysztof Piotr Malinowski, et al.
Published: (2020-10-01)

Riding the Pandemic Waves—Lessons to Be Learned from the COVID-19 Crisis Management in Romania
by: Gergő Túri, et al.
Published: (2022-06-01)

Companies’ Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study
by: Ting Wang, et al.
Published: (2020-12-01)

Prevalence, Cardiometabolic Comorbidities and Reporting of Chronic Kidney Disease; A Hungarian Cohort Analysis
by: Antal Zemplényi, et al.
Published: (2023-03-01)

Adequate effectiveness of ribociclib plus letrozole or fulvestrant in patients with advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated in routine Bulgarian clinical practice
by: Manoela Manova, et al.
Published: (2023-12-01)

How Changes in Reimbursement Practices Influence the Financial Sustainability of Medicine Policy: Lessons Learned from Slovakia
by: Tomas Tesar, et al.
Published: (2019-06-01)

Consolidated Health Economic Evaluation Reporting Standards for Interventions that use Artificial Intelligence (CHEERS-AI)
by: Elvidge, J, et al.
Published: (2024)

A systematic review of economic evaluations of pharmacological treatments for active tuberculosis
by: Sarosh Nagar, et al.
Published: (2024-04-01)